Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID

Alessandro Aiuti, Immacolata Brigida, Francesca Ferrua, Barbara Cappelli, Robert Chiesa, Sarah Marktel, Maria Grazia Roncarolo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Gene therapy is a highly attractive strategy for many types of inherited disorders of the immune system. Adenosine deaminase (ADA) deficient-severe combined immunodeficiency (SCID) has been the target of several clinical trials based on the use of hematopoietic stem/progenitor cells engineered with retroviral vectors. The introduction of a low intensity conditioning regimen has been a crucial factor in achieving stable engrafment of hematopoietic stem cells and therapeutic levels of ADA-expressing cells. Recent studies have demonstrated that gene therapy for ADA-SCID has favorable safety profile and is effective in restoring normal purine metabolism and immune functions. Stem cell gene therapy combined with appropriate conditioning regimens might be extended to other genetic disorders of the hematopoietic system.

Original languageEnglish
Pages (from-to)150-159
Number of pages10
JournalImmunologic Research
Volume44
Issue number1-3
DOIs
Publication statusPublished - 2009

Fingerprint

Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Genetic Therapy
Adenosine Deaminase
Hematopoietic System
Severe Combined Immunodeficiency
Inborn Genetic Diseases
Immune System
Stem Cells
Clinical Trials
Safety
Severe combined immunodeficiency due to adenosine deaminase deficiency
Therapeutics

Keywords

  • Bone marrow
  • Gene therapy
  • Hematopoietic stem cell
  • Retroviral vector
  • Severe combined immunodeficiency

ASJC Scopus subject areas

  • Immunology

Cite this

Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. / Aiuti, Alessandro; Brigida, Immacolata; Ferrua, Francesca; Cappelli, Barbara; Chiesa, Robert; Marktel, Sarah; Roncarolo, Maria Grazia.

In: Immunologic Research, Vol. 44, No. 1-3, 2009, p. 150-159.

Research output: Contribution to journalArticle

Aiuti, A, Brigida, I, Ferrua, F, Cappelli, B, Chiesa, R, Marktel, S & Roncarolo, MG 2009, 'Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID', Immunologic Research, vol. 44, no. 1-3, pp. 150-159. https://doi.org/10.1007/s12026-009-8107-8
Aiuti, Alessandro ; Brigida, Immacolata ; Ferrua, Francesca ; Cappelli, Barbara ; Chiesa, Robert ; Marktel, Sarah ; Roncarolo, Maria Grazia. / Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. In: Immunologic Research. 2009 ; Vol. 44, No. 1-3. pp. 150-159.
@article{e6b81f9416d34956a442bba479dfffea,
title = "Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID",
abstract = "Gene therapy is a highly attractive strategy for many types of inherited disorders of the immune system. Adenosine deaminase (ADA) deficient-severe combined immunodeficiency (SCID) has been the target of several clinical trials based on the use of hematopoietic stem/progenitor cells engineered with retroviral vectors. The introduction of a low intensity conditioning regimen has been a crucial factor in achieving stable engrafment of hematopoietic stem cells and therapeutic levels of ADA-expressing cells. Recent studies have demonstrated that gene therapy for ADA-SCID has favorable safety profile and is effective in restoring normal purine metabolism and immune functions. Stem cell gene therapy combined with appropriate conditioning regimens might be extended to other genetic disorders of the hematopoietic system.",
keywords = "Bone marrow, Gene therapy, Hematopoietic stem cell, Retroviral vector, Severe combined immunodeficiency",
author = "Alessandro Aiuti and Immacolata Brigida and Francesca Ferrua and Barbara Cappelli and Robert Chiesa and Sarah Marktel and Roncarolo, {Maria Grazia}",
year = "2009",
doi = "10.1007/s12026-009-8107-8",
language = "English",
volume = "44",
pages = "150--159",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID

AU - Aiuti, Alessandro

AU - Brigida, Immacolata

AU - Ferrua, Francesca

AU - Cappelli, Barbara

AU - Chiesa, Robert

AU - Marktel, Sarah

AU - Roncarolo, Maria Grazia

PY - 2009

Y1 - 2009

N2 - Gene therapy is a highly attractive strategy for many types of inherited disorders of the immune system. Adenosine deaminase (ADA) deficient-severe combined immunodeficiency (SCID) has been the target of several clinical trials based on the use of hematopoietic stem/progenitor cells engineered with retroviral vectors. The introduction of a low intensity conditioning regimen has been a crucial factor in achieving stable engrafment of hematopoietic stem cells and therapeutic levels of ADA-expressing cells. Recent studies have demonstrated that gene therapy for ADA-SCID has favorable safety profile and is effective in restoring normal purine metabolism and immune functions. Stem cell gene therapy combined with appropriate conditioning regimens might be extended to other genetic disorders of the hematopoietic system.

AB - Gene therapy is a highly attractive strategy for many types of inherited disorders of the immune system. Adenosine deaminase (ADA) deficient-severe combined immunodeficiency (SCID) has been the target of several clinical trials based on the use of hematopoietic stem/progenitor cells engineered with retroviral vectors. The introduction of a low intensity conditioning regimen has been a crucial factor in achieving stable engrafment of hematopoietic stem cells and therapeutic levels of ADA-expressing cells. Recent studies have demonstrated that gene therapy for ADA-SCID has favorable safety profile and is effective in restoring normal purine metabolism and immune functions. Stem cell gene therapy combined with appropriate conditioning regimens might be extended to other genetic disorders of the hematopoietic system.

KW - Bone marrow

KW - Gene therapy

KW - Hematopoietic stem cell

KW - Retroviral vector

KW - Severe combined immunodeficiency

UR - http://www.scopus.com/inward/record.url?scp=69849098671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69849098671&partnerID=8YFLogxK

U2 - 10.1007/s12026-009-8107-8

DO - 10.1007/s12026-009-8107-8

M3 - Article

VL - 44

SP - 150

EP - 159

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1-3

ER -